Primary Immunodeficiency Clinical Trials

6 recruiting

Primary Immunodeficiency Trials at a Glance

16 actively recruiting trials for primary immunodeficiency are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Bethesda, Pittsburgh, and Baltimore. Lead sponsors running primary immunodeficiency studies include National Institute of Allergy and Infectious Diseases (NIAID), Paul Szabolcs, and Takeda.

Browse primary immunodeficiency trials by phase

Treatments under study

About Primary Immunodeficiency Clinical Trials

Looking for clinical trials for Primary Immunodeficiency? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Primary Immunodeficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Primary Immunodeficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting

The Mechanistic Biology of Primary Immunodeficiency Disorders

Primary Immunodeficiency Disorders
National Institute of Allergy and Infectious Diseases (NIAID)2,500 enrolled2 locationsNCT03394053
Recruiting

NIAID Centralized Sequencing Protocol

Primary ImmunodeficiencyAtopy
National Institute of Allergy and Infectious Diseases (NIAID)20,000 enrolled2 locationsNCT03206099
Recruiting

Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

Primary Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)3,000 enrolled3 locationsNCT03610802
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

Primary Immunodeficiency Diseases (PID)
Takeda100 enrolled1 locationNCT06565078
Recruiting
Phase 1

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

Viral InfectionHematopoietic Stem Cell Transplantation (HSCT)Primary Immunodeficiency Disorders (PID)
Children's National Research Institute48 enrolled3 locationsNCT04691622
Recruiting

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)+2 more
Paul Szabolcs50 enrolled1 locationNCT04528355
Recruiting
Phase 3

Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)

Primary Immunodeficiency Diseases
Biopharma Plasma LLC56 enrolled12 locationsNCT07346859
Recruiting
Phase 2

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Juvenile Rheumatoid Arthritis (JRA)Primary Immunodeficiency (PID)Congenital Bone Marrow Failure Syndromes+4 more
Paul Szabolcs100 enrolled1 locationNCT01962415
Recruiting
Phase 4

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

Primary Immunodeficiency
CSL Behring8 enrolled8 locationsNCT07076446
Recruiting
Not Applicable

Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders

Primary Immunodeficiency Diseases (PID)
prof. dr. Rik Schrijvers20 enrolled1 locationNCT07261891
Recruiting

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

Autoimmune HepatitisSystemic Lupus ErythematosusHemophagocytic Lymphohistiocytoses+17 more
Institut National de la Santé Et de la Recherche Médicale, France500 enrolled1 locationNCT04902807
Recruiting
Not Applicable

Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency

Primary Immunodeficiency Diseases (PID)
Dr. Hatice Dönmez32 enrolled1 locationNCT07004803
Recruiting
Phase 3

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Takeda39 enrolled5 locationsNCT06076642
Recruiting
Not Applicable

Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency

Primary Immunodeficiency
Gazi University40 enrolled1 locationNCT06092528